BTIG Research Issues Pessimistic Forecast for Tvardi Therapeutics (NASDAQ:TVRD) Stock Price

Tvardi Therapeutics (NASDAQ:TVRD) had its target price dropped by BTIG Research to $5.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 145.82% from the stock’s current price.

TVRD has been the topic of several other reports. Wall Street Zen lowered Tvardi Therapeutics to a “strong sell” rating in a research report on Saturday, July 18th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. HC Wainwright began coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 price target on the stock. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a report on Wednesday, July 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Trading Down 5.0%

Shares of NASDAQ TVRD traded down $0.11 during midday trading on Thursday, reaching $2.03. 231,818 shares of the stock were exchanged, compared to its average volume of 1,031,862. The company has a market capitalization of $19.08 million, a P/E ratio of -0.65 and a beta of 0.39. Tvardi Therapeutics has a 52-week low of $1.50 and a 52-week high of $43.65. The stock has a 50 day moving average price of $2.82 and a 200-day moving average price of $3.41.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). On average, analysts forecast that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds have recently modified their holdings of the company. Arax Advisory Partners lifted its holdings in shares of Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics during the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the second quarter worth about $43,000. HRT Financial LP bought a new stake in Tvardi Therapeutics in the fourth quarter worth about $47,000. Finally, XTX Topco Ltd acquired a new stake in Tvardi Therapeutics in the 4th quarter valued at about $55,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.